New delivery systems to improve the bioavailability of resveratrol

Expert Opinion on Drug Delivery

Volumn 8, Issue 8, 2011, Pages 973-990

  Santos, Ana Cláudia ^a   Veiga, Francisco ^a   Ribeiro, António J ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Bioavailability; New delivery systems; Pharmacokinetics; Resveratrol; Stability

Indexed keywords

ACOUSTICALLY ACTIVE LIPOSPHERE; ASIALOFETUIN; CHITOSAN; CYCLODEXTRIN; DIHYDRORESVERATROL; DRUG CARRIER; DRUG METABOLITE; GELATIN; GLYCOPROTEIN; IMMUNOGLOBULIN; LIPOSOME; MELANIN; MICROSPHERE; NANOPARTICLE; NANOSPHERE; PHENOL DERIVATIVE; PICEID; RESVERATROL; RESVERATROL 3 O 4' O DISULFATE; RESVERATROL 3 O GLUCOSIDE; RESVERATROL 3 O GLUCURONIDE; RESVERATROL 3 O SULFATE; RESVERATROL 3 SULFATE; RESVERATROL 3,4' DISULFATE; RESVERATROL 3,5 DISULFATE; RESVERATROL 4 O GLUCOSIDE; RESVERATROL 4' O GLUCURONIDE; RESVERATROL 4' O SULFATE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BIOLOGICAL ACTIVITY; CARDIOVASCULAR PROTECTION; CIS TRANS ISOMERISM; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG OXIDATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TRANSPORT; FIRST PASS EFFECT; GLUCURONIDATION; HUMAN; HYDROPHOBICITY; LIVER METABOLISM; LOZENGE; MACROMOLECULE; MICELLE; MICROBUBBLE; MICROENCAPSULATION; NEUROPROTECTION; NONHUMAN; POWDER; REVIEW; TABLET FORMULATION;

ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; HUMANS; STILBENES;

EID: 79960768800     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2011.581655     Document Type: Review

References (98)

1. de la Lastra CA, Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans 2007;35(5):1156-60 (Pubitemid 350206449)
2. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J 2003;17(14):1975-85 (Pubitemid 37392442)
3. Kristl J, Teskac K, Caddeo C, et al. Improvements of cellular stress response on resveratrol in liposomes. Eur J Pharm Biopharm 2009;73(2):253-9
4. Gulcin I. Antioxidant properties of resveratrol: A structure-activity insight. Innovat Food Sci Emerg Tech 2010;11(1):210-18
5. Jensen J, Wertz C, O'Neill V. Preformulation stability of trans-resveratrol and trans-resveratrol glucoside (Piceid). J Agric Food Chem 2010;58(3):1685-90
6. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006;5(6):493-506 (Pubitemid 44136961)
7. Burkon A, Somoza V. Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O- conjugated diglucuronides - two novel resveratrol metabolites in human plasma. Mol Nutr Food Res 2008;52(5):549-57
8. Shi G, Rao L, Yu H, et al. Stabilization and encapsulation of photosensitive resveratrol within yeast cell. Int J Pharm 2008;349(1-2):83-93 (Pubitemid 350299698)
9. Juhasz B, Varga B, Gesztelyi R, et al. Resveratrol: a multifunctional cytoprotective molecule. Curr Pharm Biotechnol 2010;11(8):810-18
10. Grill JD, Cummings JL. Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev Neurother 2010;10(5):711-28
11. Sun AY, Wang Q, Simonyi A, et al. Resveratrol as a Therapeutic Agent for Neurodegenerative Diseases. Mol Neurobiol 2010;41(2-3):375-83
12. Gatouillat G, Balasse E, Joseph-Pietras D, et al. Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma. J Cell Biochem 2010;110(4):893-902
13. Subramanian L, Youssef S, Bhattacharya S. Resveratrol: challenges in translation to the clinic - a critical discussion. Clin Cancer Res 2010;16(24):5942-8
14. Kroon PA, Iyer A, Chunduri P, et al. The cardiovascular nutrapharmacology of resveratrol: pharmacokinetics, molecular mechanisms and therapeutic potential. Curr Med Chem 2010;17(23):2442-55
15. Tsunoda I, Rose JW, Rojas M, et al. Treatment of an animal model for multiple sclerosis with resveratrol, a natural compound in red wine. J Neuroimmunol 2008;203(2):247
16. Cui X, Jin Y, Hofseth AB, et al. Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev Res (Phila Pa) 2010;3(4):549-59
17. Jha RK, Ma Q, Sha H, et al. Protective effect of resveratrol in severe acute pancreatitis-induced brain injury. Pancreas 2009;38(8):947-53
18. Almeida L, Vaz-da-Silva M, Falcao A, et al. Pharmacokinetic and safety profile of trans-resveratrol in a rising multiple-dose study in healthy volunteers. Mol Nutr Food Res 2009;53(1):7-15
19. Lu X, Ji C, Xu H, et al. Resveratrol-loaded polymeric micelles protect cells from Abeta-induced oxidative stress. Int J Pharm 2009;37(1-2):89-96
20. Caddeo C, Teskac K, Sinico C, et al. Effect of resveratrol incorporated in liposomes on proliferation and UV-B protection of cells. Int J Pharm 2008;363(1-2):183-91
21. Lopez-Nicolas JM, Rodriguez-Bonilla P, Garcia-Caramona F. Complexation of Pinosylvin, an analogue of resveratrol with high antifungal and antimicrobial activity, by different types of cyclodextrins. J Agric Food Chem 2009;57(21):10175-80
22. Ros RZ. Resveratrol: marcador biologic I dietetic de consum de vi. Barcelona: 2008
23. Henry C, Vitrac X, Decendit A, et al. Cellular uptake and efflux of trans-piceid and its aglycone trans-resveratrol on the apical membrane of human intestinal Caco-2 cells. J Agric Food Chem 2005;53(3):798-803 (Pubitemid 40194406)
24. Kuhnle G, Spencer JP, Chowrimootoo G, et al. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun 2000;272(1):212-17 (Pubitemid 30444924)
25. Walle T, Hsieh F, DeLegge MH, et al. High absortion but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004;32(12):1377-82 (Pubitemid 39564557)
26. Das S, Lin HS, Ho PC, et al. The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm Res 2008;25(11):2593-600
27. Kapetanovic IM, Muzzio M, Huang Z, et al. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother Pharmacol 20 Nov 2010; [Epub ahead of print]
28. Zhou M, Chen X, Zhong D. Simultaneous determination of trans-resveratrol-3-O-glucoside and its two metabolites in rat plasma using liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007;854(1-2):219-23 (Pubitemid 46962386)
29. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 2005;49(5):472-81 (Pubitemid 40780394)
30. Miksits M, Maier-Salamon A, Aust S, et al. Sulfation of resveratrol in human liver: Evidence of a major role for the sulfotransferases SULT1A1 and SULT1E1. Xenobiotica 2005;35(12):1101-19 (Pubitemid 43163249)
31. Marier JF, Vachon P, Gritsas A, et al. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J Pharmacol Exp Ther 2002;302(1):369-73 (Pubitemid 34680460)
32. Boocock DJ, Faust GE, Patel KR, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007;16(6):1246-52 (Pubitemid 46984966)
33. Ortuno J, Covas MI, Farre M, et al. Matrix effects on the bioavailability of resveratrol in humans. Food Chem 2010;120(4):1123-30
34. Urpi-Sarda M, Jauregui O, Lamuela-Raventos RM, et al. Uptake of diet resveratrol into the human low-density lipoprotein. Identification and quantification of resveratrol metabolites by liquid chromatography coupled with tandem mass spectrometry. Anal Chem 2005;77(10):3149-55 (Pubitemid 40695470)
35. Urpi-Sarda M, Zamora-Ros R, Lamuela-Raventos R, et al. HPLC-tandem mass spectrometric method to characterize resveratrol metabolism in humans. Clin Chem 2007;53(2):292-9 (Pubitemid 46338274)
36. Elliott PJ, Jirousek M. Sirtuins: novel targets for metabolic disease. Curr Opin Investig Drugs 2008;9(4):371-8 (Pubitemid 351507663)
37. Vitaglione P, Sforza S, Galaverna G, et al. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res 2005;49(5):495-504 (Pubitemid 40780396)
38. Boocock DJ, Patel KR, Faust GE, et al. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2007;848(2):182-7 (Pubitemid 46464044)
39. Wenzel E, Soldo T, Erbersdobler H, et al. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 2005;49(5):482-94 (Pubitemid 40780395)
40. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C, et al. Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 2010;54(1):7-16
41. Orallo F. Comparative studies of the antioxidant effects of cis- and trans-resveratrol. Curr Med Chem 2006;13(1):87-98
42. Gescher AJ, Steward WP. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev 2003;12(10):953-7 (Pubitemid 37310248)
43. Athar M, Back JH, Tang X, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007;224(3):274-83 (Pubitemid 47575677)
44. Juan ME, Wenzel U, Daniel H, et al. Resveratrol induces apoptosis through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells. J Agric Food Chem 2008;56(12):4813-18 (Pubitemid 351999415)
45. Dudley J, Das S, Mukherjee S, et al. Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem 2009;20(6):443-52
46. Jang MH, Piao XL, Kim HY, et al. Resveratrol oligomers from Vitis amurensis attenuate beta-amyloid-induced oxidative stress in PC12 cells. Biol Pharm Bull 2007;30(6):1130-4 (Pubitemid 46883881)
47. Sharma V, McNeill JH. To scale or not to scale: the principles of dose extrapolation. Br J Pharmacol 2009;157(6):907-21
48. Zamora-Ros R, Urpi-Sarda M, Lamuela-Raventos RM, et al. Diagnostic performance of urinary resveratrol metabolites as a biomarker of moderate wine consumption. Clin Chem 2006;52(7):1373-80 (Pubitemid 43956030)
49. Zamora-Ros R, Urpi-Sarda M, Lamuela-Raventos RM, et al. Resveratrol metabolites in urine as a biomarker of wine intake in free-living subjects: the PREDIMED study. Free Radic Biol Med 2009;46(12):1561
50. Suri S, Liu XH, Rayment S, et al. Quercetin and its major metabolites selectively modulate cyclic GMP-dependent relaxations and associated tolerance in pig isolated coronary artery. Br J Pharmacol 2010;159(3):566-75
51. Tribolo S, Lodi F, Connor C, et al. Comparative effects of quercetin and its predominant human metabolites on adhesion molecule expression in activated human vascular endothelial cells. Atherosclerosis 2008;197(1):50-6 (Pubitemid 351273272)
52. Shu XH, Li H, Sun Z, et al. Identification of metabolic pattern and bioactive form of resveratrol in human medulloblastoma cells. Biochem Pharmacol 2010;79(10):1516-25
53. Miksits M, Wlcek K, Svoboda M, et al. Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. Planta Med 2009;75(11):1227-30
54. Wang LX, Heredia A, Song H, et al. Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity. J Pharm Sci 2004;93(10):2448-57 (Pubitemid 39319429)
55. Mikulski D, Gorniak R, Molski M. A theoretical study of the structure-radical scavenging activity of trans-resveratrol analogues and cis-resveratrol in gas phase and water environment. Eur J Med Chem 2010;45(3):1015-27
56. Orsini F, Verotta L, Lecchi M, et al. Resveratrol derivatives and their role as potassium channels modulators. J Nat Prod 2004;67(3):421-6 (Pubitemid 38405706)
57. Asensi M, Medina I, Ortega A, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 2002;33(3):387-98 (Pubitemid 34786278)
58. Regev-Shoshani G, Shoseyov O, Bilkis I, et al. Glycosylation of resveratrol protects it from enzymatic oxidation. Biochem J 2003;374(Pt 1):157-63 (Pubitemid 37046939)
59. Pervaiz S, Holme AL. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal 2009;11(11):2851-97
60. Hu M. Commentary: bioavailability of flavonoids and polyphenols: call to arms. Mol Pharm 2007;4(6):803-6
61. Fuchs S, Kutscher M, Hertel T, et al. Transglutaminase: new insights into gelatin nanoparticle cross-linking. J Microencapsul 2010;27(8):747-54
62. Peter M, Binulal NS, Nair SV, et al. Novel biodegradable chitosan-gelatin/ nano-bioactive glass ceramic composite scaffolds for alveolar bone tissue engineering. Chem Eng J 2010;158(2):353-61
63. Atanackovic M, Posa M, Heinle H, et al. Solubilization of resveratrol in micellar solutions of different bile acids. Colloids Surf B Biointerfaces 2009;72(1):148-54
64. Pinto Reis C, Neufeld RJ, Ribeiro AJ, et al. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2006;2(1):8-21
65. Borgogna M, Bellich B, Zorzin L, et al. Food microencapsulation of bioactive compounds: Rheological and thermal characterisation of non-conventional gelling system. Food Chem 2010;122(2):416-23
66. 2008017415-A1; 2008 04-22-2010
67. Nam J-B, Ryu J-H, Kim J-W, et al. Stabilization of resveratrol immobilized in monodisperse cyano-functionalized porous polymeric microspheres. Polymer (Guildf) 2005;46(21):8956-63 (Pubitemid 41328574)
68. Das S, Ng KY. Colon-specific delivery of resveratrol: Optimization of multi-particulate calcium-pectinate carrier. Int J Pharm 2009;385(1-2):20-8
69. Peng H, Xiong H, Li J, et al. Vanillin cross-linked chitosan microspheres for controlled release of resveratrol. Food Chem 2010;121(1):23-8
70. Lu Z, Cheng B, Hu Y, et al. Complexation of resveratrol with cyclodextrins: Solubility and antioxidant activity. Food Chem 2009;113(1):17-20
71. Shao J, Li X, Lu X, et al. Enhanced growth inhibition effect of resveratrol incorporated into biodegradable nanoparticles against glioma cells is mediated by the induction of intracellular reactive oxygen species levels. Colloids Surf B Biointerfaces 2009;72(1):40-7
72. Teskac K, Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol. Int J Pharm 2010;390(1):61-9
73. Fang JY, Hung CF, Liao MH, et al. A study of the formulation design of acoustically active lipospheres as carriers for drug delivery. Eur J Pharm Biopharm 2007;67(1):67-75
74. Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci 2007;32(8-9):1054-82 (Pubitemid 47198293)
75. Han DW, Lee JJ, Jung DY, et al. Development of epigallocatechin gallate-eluting polymeric stent and its physicochemical, biomechanical and biological evaluations. Biomed Mater 2009;4(4):044104 Available online at: http://iopscience.iop.org/1748-605X/4/4/044104 [Last accessed 18 May]
76. Italia JL, Datta P, Ankola DD, et al. Nanoparticles enhance per oral bioavailability of poorly available molecules: epigallocatechin gallate nanoparticles ameliorates cyclosporine induced nephrotoxicity in rats at three times lower dose than oral solution. J Biomed Nanotechnol 2008;4(3):304-12
77. Sahu A, Bora U, Kasoju N, et al. Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. Acta Biomater 2008;4(6):1752-61
78. Thangapazham RL, Puri A, Tele S, et al. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol 2008;32(5):1119-23
79. Das RK, Kasoju N, Bora U. Encapsulation of curcumin in alginate-chitosan-pluronic composite nanoparticles for delivery to cancer cells. Nanomedicine 2010;6(1):153-60
80. Merrell JG, McLaughlin SW, Tie L, et al. Curcumin-loaded poly(epsiloncaprolactone) nanofibres: diabetic wound dressing with anti-oxidant and anti-inflammatory properties. Clin Exp Pharmacol Physiol 2009;36(12):1149-56
81. Li J, Wang Y, Yang C, et al. Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1. Mol Pharmacol 2009;76(1):81-90
82. Hu Y, Jiang X, Ding Y, et al. Preparation and drug release behaviors of nimodipine-loaded poly(caprolactone)- poly(ethylene oxide)-polylactide amphiphilic copolymer nanoparticles. Biomaterials 2003;24(13):2395-404 (Pubitemid 36434059)
83. Zhang L, Hu Y, Jiang X, et al. Camptothecin derivative-loaded poly (caprolactone-co-lactide)-b-PEG-b-poly (caprolactone-co-lactide) nanoparticles and their biodistribution in mice. J Control Release 2004;96(1):135-48 (Pubitemid 38438496)
84. Narayanan NK, Nargi D, Randolph C, et al. Liposome encapsulation of curcumin and resveratrol in combinationreduces prostate cancer incidence in PTEN knockout mice. Int J Cancer 2009;125(1):1-8
85. Kennedy DO, Wightman EL, Reay JL, et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J for Clin Nutr 2010;91(6):1590-7
86. Liao PC, Ng LT, Lin LT, et al. Resveratrol arrests cell cycle and induces apoptosis in human hepatocellular carcinoma Huh-7 cells. J Med Food 2010;13(6):1415-23
87. Quincozes-Santos A, Gottfried C. Resveratrol modulates astroglial functions: neuroprotective hypothesis. Ann NY Acad Sci 2011;1215(1):72-8
88. Zhang H, Zhang J, Ungvari Z. Resveratrol Improves endothelial function: role of TNF{alpha} and vascular oxidative stress. Arterioscler Thromb Vasc Biol 2009;29(8):1164-71
89. Csiszar A, Labinskyy N, Pinto JT, et al. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol 2009;297(1):H13-20
90. Ungvari Z, Bagi Z, Feher A, et al. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am J Physiol Heart Circ Physiol 2010;299(1):H18-24
91. Meng X, Maliakal P, Lu H, et al. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 2004;52(4):935-42
92. Soleas GJ, Yan J, Goldberg DM. Ultrasensitive assay for three polyphenols (catechin, quercetin and resveratrol) and their conjugates in biological fluids utilizing gas chromatography with mass selective detection. J Chromatogr B Biomed Sci Appl 2001;757(1):161-72 (Pubitemid 32424469)
93. Soleas GJ, Yan J, Goldberg DM. Measurement of trans-resveratrol, (+)-catechin, and quercetin in rat and human blood and urine by gas chromatography with mass selective detection. Methods Enzymol 2001;335:130-45 (Pubitemid 32507233)
94. Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 2003;36(1):79-87 (Pubitemid 36126394)
95. la Porte C, Voduc N, Zhang G, et al. Steady-state pharmacokinetics and tolerability of trans-resveratrol 2000 mg twice daily with food, quercetin and alcohol (ethanol) in healthy human subjects. Clinic Pharmacokinet 2010;49(7):449-54
96. Ohguchi K, Tanaka T, Ito T, et al. Inhibitory effects of resveratrol derivatives from dipterocarpaceae plants on tyrosinase activity. Biosci Biotechnol Biochem 2003;67(7):1587-9 (Pubitemid 39251801)
97. Arigony Souto A. Resveratrol/ cyclodextrin compound-containing water soluble complex e.g. for treating inflammation is prepared by adding cyclodextrin, organic solvent and resveratrol compound, heating, cooling and separating crystal. Eurofarma Lab Ltda; Uniao Brasileira Educacao E Assistencia Mantenedora Da Pucrs; Uniao Brasileira Educacao E Assistenci. 2009
98. Altiok D, Altiok E, Bayraktar O, et al. Stability of trans-Resveratrol Incorporated in Chitosan Microspheres. 2009 14th National Biomedical Engineering Meeting; Biyomut; 2009. p. 360-3